These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 10078728)
21. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia. Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890 [TBL] [Abstract][Full Text] [Related]
22. Neuroleptic malignant syndrome during a change from haloperidol to risperidone. Reeves RR; Mack JE; Torres RA Ann Pharmacother; 2001 Jun; 35(6):698-701. PubMed ID: 11408988 [TBL] [Abstract][Full Text] [Related]
23. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. Jeste DV; Lacro JP; Bailey A; Rockwell E; Harris MJ; Caligiuri MP J Am Geriatr Soc; 1999 Jun; 47(6):716-9. PubMed ID: 10366172 [TBL] [Abstract][Full Text] [Related]
24. Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. Kim JH; Byun HJ J Clin Pharm Ther; 2007 Oct; 32(5):461-7. PubMed ID: 17875112 [TBL] [Abstract][Full Text] [Related]
25. A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database. Fleischhacker WW; Lemmens P; van Baelen B Pharmacopsychiatry; 2001 May; 34(3):104-10. PubMed ID: 11434401 [TBL] [Abstract][Full Text] [Related]
26. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871 [TBL] [Abstract][Full Text] [Related]
27. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. David SR; Taylor CC; Kinon BJ; Breier A Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906 [TBL] [Abstract][Full Text] [Related]
28. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. Soyka M; Winter C; Kagerer S; Brunnauer M; Laux G; Möller HJ J Psychiatr Res; 2005 Jan; 39(1):101-8. PubMed ID: 15504428 [TBL] [Abstract][Full Text] [Related]
29. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Villari V; Rocca P; Fonzo V; Montemagni C; Pandullo P; Bogetto F Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):405-13. PubMed ID: 17900775 [TBL] [Abstract][Full Text] [Related]
30. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740 [TBL] [Abstract][Full Text] [Related]
32. Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia. Hempel RJ; Tulen JH; van Beveren NJ; Röder CH; Hengeveld MW J Psychopharmacol; 2009 Aug; 23(6):697-707. PubMed ID: 18562420 [TBL] [Abstract][Full Text] [Related]
33. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268 [TBL] [Abstract][Full Text] [Related]
34. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Marder SR; Glynn SM; Wirshing WC; Wirshing DA; Ross D; Widmark C; Mintz J; Liberman RP; Blair KE Am J Psychiatry; 2003 Aug; 160(8):1405-12. PubMed ID: 12900301 [TBL] [Abstract][Full Text] [Related]
35. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702 [TBL] [Abstract][Full Text] [Related]
36. Risperidone in the treatment of schizophrenia. Marder SR; Meibach RC Am J Psychiatry; 1994 Jun; 151(6):825-35. PubMed ID: 7514366 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959 [TBL] [Abstract][Full Text] [Related]
38. Adverse effects of risperidone on eye movement activity: a comparison of risperidone and haloperidol in antipsychotic-naive schizophrenic patients. Sweeney JA; Bauer KS; Keshavan MS; Haas GL; Schooler NR; Kroboth PD Neuropsychopharmacology; 1997 Mar; 16(3):217-28. PubMed ID: 9138438 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania. Ouyang WC; Hsu MC; Yeh IN; Kuo CC Int J Psychiatry Clin Pract; 2012 Sep; 16(3):178-88. PubMed ID: 22404731 [TBL] [Abstract][Full Text] [Related]
40. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. Fang M; Chen H; Li LH; Wu R; Li Y; Liu L; Ye M; Huang J; Zhu S; Wang G; Zhang Q; Zheng H; Zhang L; Wang B; Zhou J; Zhao JP Int Clin Psychopharmacol; 2012 Mar; 27(2):107-13. PubMed ID: 22233697 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]